Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Brief description not available

Neuronal injury is the major pathology caused by CNS injuries like stroke or spinal cord injury. However, currently available biomarkers for CNS injuries are either not expressed in neurons at all, or are expressed constitutively in all neurons, regardless of whether the neurons are injured or not. ATF3 as a CNS injury biomarker is revolutionary because its baseline expression in CNS is very low, and it is rapidly induced only in CNS neurons shortly after CNS injuries like stroke or spinal cord injury.  Of note, human serum ATF3 level can be easily measured by a commercially available ELISA kit.

Brief description not available

Brief description not available

Brief description not available

Brief description not available

UCSF scientists have developed a novel biophysical-biochemical screening platform to identify small molecules that prevent the oligomerization of alpha-synuclein: the rate-limiting step in the formation of toxic fibrils in the pathologies of Parkinson’s disease, Lewy Body Dementia, and other neurodegenerative diseases. With this technology, novel families of small molecules have been found with the capacity to reverse multiple pathogenic markers of disease progression in cells.

This invention is a novel technology developed to treat a patient’s neurological and/or psychiatric conditions. It consists of a system of implantable devices and computational algorithms that not only has autonomous control in sensing and stimulation of electrical signals in the patient’s brain, but also enables interactions with the external environment, thereby enhancing training and learning.

This invention has provided methods for detecting dyskinesia in Parkinson’s disease patients and provided a way to titrate current treatment to maximize benefits while minimizing side effects.

This invention comprises compositions and methods for treatment of neuromyelitis optica (NMO) spectrum disorders using anti-aquaporin-4 (AQP4) antibody lacking effector function.

An adjustable step cannula to minimize therapeutic agent leakage and maximize on-target drug delivery. This new cannula design improves brain drug delivery over current fixed-length step cannulas.